(TAK) Takeda Pharmaceutical - Ratings and Ratios

Exchange: NYSE • Country: Japan • Currency: USD • Type: Common Stock • ISIN: US8740602052

Oncology, Gastroenterology, Immunology, Rare Diseases, Plasma Therapies

Pharmaceuticals
Market Cap in USD: 51,979m

IPO / Inception: 2008-10-27
12m vs SPY: 8.74%

EPS (Earnings per Share)

EPS CAGR: -0.32%
EPS Trend: 3.5%

Last SUE: 0.00
Qual. Beats: 0

Revenue

Rev. CAGR: 5.78%
Rev. Trend: 76.7%

Last SUE: -0.04
Qual. Beats: 0

Dividends

Dividend Yield	4.48%
Yield on Cost 5y	4.47%
Yield CAGR 5y	-2.95%
Payout Consistency	92.3%
Payout Ratio	0.4%

Risk via 5d forecast
Volatility	18.5%
Value at Risk 5%th	29.8%
Relative Tail Risk	-2.05%

Reward TTM
Sharpe Ratio	1.14
Alpha	20.26
CAGR/Max DD	0.24

Character TTM
Hurst Exponent	0.540
Beta	0.226
Beta Downside	0.191

Drawdowns 3y
Max DD	23.25%
Mean DD	10.14%
Median DD	10.03%

Description: TAK Takeda Pharmaceutical December 04, 2025

Takeda Pharmaceutical Co. (NYSE:TAK) is a global, Japan-based drug developer that conducts R&D, manufacturing, marketing, and out-licensing across a broad therapeutic portfolio-including gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. Its commercial brands span Entyvio, Velcade, Adcetris, and many others, while the firm maintains an extensive network of in-license, collaboration, and licensing agreements with partners such as BioMarin, GSK, Seagen, and Arrowhead to broaden its pipeline.

Key recent metrics: FY2023 revenue was roughly $30 billion, with R&D spending representing about 10 % of sales, reflecting a continued focus on high-margin specialty drugs. The gastrointestinal franchise (Entyvio) and the oncology pipeline (e.g., Adcetris, Iclusig) are the primary growth engines, together accounting for > 30 % of net sales. A sector-wide driver is the aging population in Japan and the U.S., which is expanding demand for rare-disease and biologic therapies-segments where Takeda holds a competitive advantage.

For a deeper dive into Takeda’s valuation metrics and peer comparison, you may find the ValueRay platform a useful next step.

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (33.03b TTM) > 0 and > 6% of Revenue (6% = 265.02b TTM)

FCFTA 0.07 (>2.0%) and ΔFCFTA 2.31pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 17.68% (prev 14.67%; Δ 3.01pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 1199.57b > Net Income 33.03b (YES >=105%, WARN >=100%)

Net Debt (3963.83b) to EBITDA (1130.17b) ratio: 3.51 <= 3.0 (WARN <= 3.5)

Current Ratio 1.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (3.15b) change vs 12m ago -2.02% (target <= -2.0% for YES)

Gross Margin 64.60% (prev 65.95%; Δ -1.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 30.42% (prev 31.20%; Δ -0.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.92 (EBITDA TTM 1130.17b / Interest Expense TTM 190.83b) >= 6 (WARN >= 3)

Altman Z'' 1.19

(A) 0.05 = (Total Current Assets 2920.62b - Total Current Liabilities 2139.66b) / Total Assets 14470.30b

(B) 0.08 = Retained Earnings (Balance) 1148.66b / Total Assets 14470.30b

(D) 0.39 = Book Value of Equity 2839.82b / Total Liabilities 7338.61b

Total Rating: 1.19 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 60.52

1. Piotroski 3.50pt

2. FCF Yield 8.03%

3. FCF Margin 22.14%

4. Debt/Equity 0.65

5. Debt/Ebitda 3.51

6. ROIC - WACC (= -2.78)%

7. RoE 0.47%

8. Rev. Trend 76.73%

9. EPS Trend 3.53%

What is the price of TAK shares?

As of January 13, 2026, the stock is trading at USD 16.31 with a total of 3,212,410 shares traded.
Over the past week, the price has changed by +3.95%, over one month by +13.34%, over three months by +18.88% and over the past year by +31.34%.

Is TAK a buy, sell or hold?

Takeda Pharmaceutical has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy TAK.

Strong Buy: 3
Buy: 0
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the TAK price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	17.7	8.8%
Analysts Target Price	17.7	8.8%
ValueRay Target Price	17.5	7.5%

TAK Fundamental Data Overview January 06, 2026

Market Cap JPY = 8220.20b (51.98b USD * 158.1433 USD.JPY)
P/E Trailing = 223.1429
P/E Forward = 11.0619
P/S = 0.0118
P/B = 1.0825
P/EG = 0.3444
Beta = 0.027
Revenue TTM = 4417.01b JPY
EBIT TTM = 366.65b JPY
EBITDA TTM = 1130.17b JPY
Long Term Debt = 4351.46b JPY (from longTermDebt, last quarter)
Short Term Debt = 293.86b JPY (from shortTermDebt, last quarter)
Debt = 4645.32b JPY (from shortLongTermDebtTotal, last quarter)
Net Debt = 3963.83b JPY (from netDebt column, last quarter)
Enterprise Value = 12184.04b JPY (8220.20b + Debt 4645.32b - CCE 681.49b)
Interest Coverage Ratio = 1.92 (Ebit TTM 366.65b / Interest Expense TTM 190.83b)
EV/FCF = 12.46x (Enterprise Value 12184.04b / FCF TTM 977.79b)
FCF Yield = 8.03% (FCF TTM 977.79b / Enterprise Value 12184.04b)
FCF Margin = 22.14% (FCF TTM 977.79b / Revenue TTM 4417.01b)
Net Margin = 0.75% (Net Income TTM 33.03b / Revenue TTM 4417.01b)
Gross Margin = 64.60% ((Revenue TTM 4417.01b - Cost of Revenue TTM 1563.71b) / Revenue TTM)
Gross Margin QoQ = 65.85% (prev 65.24%)
Tobins Q-Ratio = 0.84 (Enterprise Value 12184.04b / Total Assets 14470.30b)
Interest Expense / Debt = 1.79% (Interest Expense 83.14b / Debt 4645.32b)
Taxrate = 38.23% (66.94b / 175.08b)
NOPAT = 226.47b (EBIT 366.65b * (1 - 38.23%))
Current Ratio = 1.36 (Total Current Assets 2920.62b / Total Current Liabilities 2139.66b)
Debt / Equity = 0.65 (Debt 4645.32b / totalStockholderEquity, last quarter 7130.70b)
Debt / EBITDA = 3.51 (Net Debt 3963.83b / EBITDA 1130.17b)
Debt / FCF = 4.05 (Net Debt 3963.83b / FCF TTM 977.79b)
Total Stockholder Equity = 7087.33b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.23% (Net Income 33.03b / Total Assets 14470.30b)
RoE = 0.47% (Net Income TTM 33.03b / Total Stockholder Equity 7087.33b)
RoCE = 3.21% (EBIT 366.65b / Capital Employed (Equity 7087.33b + L.T.Debt 4351.46b))
RoIC = 1.93% (NOPAT 226.47b / Invested Capital 11714.00b)
WACC = 4.71% (E(8220.20b)/V(12865.52b) * Re(6.75%) + D(4645.32b)/V(12865.52b) * Rd(1.79%) * (1-Tc(0.38)))
Discount Rate = 6.75% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.24%
[DCF Debug] Terminal Value 84.62% ; FCFF base≈845.77b ; Y1≈723.84b ; Y5≈561.38b
Fair Price DCF = 4153 (EV 17083.46b - Net Debt 3963.83b = Equity 13119.62b / Shares 3.16b; r=5.90% [WACC]; 5y FCF grow -17.51% → 2.90% )
EPS Correlation: 3.53 | EPS CAGR: -0.32% | SUE: -0.00 | # QB: 0
Revenue Correlation: 76.73 | Revenue CAGR: 5.78% | SUE: -0.04 | # QB: 0
EPS current Year (2026-03-31): EPS=73.97 | Chg30d=-0.590 | Revisions Net=-1 | Growth EPS=+117.6% | Growth Revenue=+677.1%
EPS next Year (2027-03-31): EPS=122.17 | Chg30d=-0.974 | Revisions Net=-1 | Growth EPS=+65.2% | Growth Revenue=+0.5%

Additional Sources for TAK Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle